SELECT * FROM `stock_list` WHERE `symbol` = "ISPC" and stock_list.exchange IN (SELECT exchange FROM gurufocu_main.stock_list_exchanges where country='USA' and active=1) limit 0,1
SELECT * FROM `stock_list` where symbol='ISPC' AND exchange = 'NAS' limit 0,1
SELECT * FROM `stock_list` WHERE `symbol` = "ISPC" and stock_list.exchange IN (SELECT exchange FROM gurufocu_main.stock_list_exchanges where country='USA' and active=1) limit 0,1 ISPC (iSpecimen) Capex-to-Operating-Cash-Flow
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » iSpecimen Inc (NAS:ISPC) » Definitions » Capex-to-Operating-Cash-Flow

iSpecimen (iSpecimen) Capex-to-Operating-Cash-Flow : 2.99 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is iSpecimen Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

iSpecimen's Capital Expenditure for the three months ended in Dec. 2023 was $-1.03 Mil. Its Cash Flow from Operations for the three months ended in Dec. 2023 was $0.35 Mil.

Hence, iSpecimen's Capex-to-Operating-Cash-Flow for the three months ended in Dec. 2023 was 2.99.


iSpecimen Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for iSpecimen's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iSpecimen Capex-to-Operating-Cash-Flow Chart

iSpecimen Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial - - - - -

iSpecimen Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 2.99

Competitive Comparison of iSpecimen's Capex-to-Operating-Cash-Flow

For the Diagnostics & Research subindustry, iSpecimen's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


iSpecimen's Capex-to-Operating-Cash-Flow Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, iSpecimen's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where iSpecimen's Capex-to-Operating-Cash-Flow falls into.



iSpecimen Capex-to-Operating-Cash-Flow Calculation

iSpecimen's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-4.745) / -5.808
=N/A

iSpecimen's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-1.032) / 0.345
=2.99

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


iSpecimen  (NAS:ISPC) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


iSpecimen Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of iSpecimen's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


iSpecimen (iSpecimen) Business Description

Traded in Other Exchanges
N/A
Address
450 Bedford Street, Lexington, MA, USA, 02420
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.
Executives
Benjamin Bielak officer: Chief Information Officer 450 BEDFORD STREET, LEXINGTON MA 02420
Tracy Curley officer: Chief Financial Officer 450 BEDFORD STREET, LEXINGTON MA 02420
Joseph J. Basile director 450 BEDFORD STREET, LEXINGTON MA 02420
Andrew L. Ross director, 10 percent owner 450 BEDFORD STREET, LEXINGTON MA 02420
Gullans Steven R. Ph.d. director C/O EXCEL VENTURE MANAGEMENT, LLC, 800 BOYLSTON ST., STE 2825, BOSTON MA 02199
John L Brooks director 100 LOWDER BROOK DRIVE SUITE 2500, WESTWOOD MA 02090
Obf Investments, Llc 10 percent owner 450 BEDFORD STREET, LEXINGTON MA 02420
Margaret H. Lawrence director 450 BEDFORD STREET, LEXINGTON MA 02420
George H. Scholl director 450 BEDFORD STREET, LEXINGTON MA 02420
Christopher Ianelli director, officer: CEO, President 450 BEDFORD STREET, LEXINGTON MA 02420
Jill Mullan director, officer: COO, Secretary, Treasurer 450 BEDFORD STREET, LEXINGTON MA 02420